EP1917967A1 - Anti-aids drug - Google Patents

Anti-aids drug Download PDF

Info

Publication number
EP1917967A1
EP1917967A1 EP05751388A EP05751388A EP1917967A1 EP 1917967 A1 EP1917967 A1 EP 1917967A1 EP 05751388 A EP05751388 A EP 05751388A EP 05751388 A EP05751388 A EP 05751388A EP 1917967 A1 EP1917967 A1 EP 1917967A1
Authority
EP
European Patent Office
Prior art keywords
aids
agent
mentha
stevia
dried
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05751388A
Other languages
German (de)
French (fr)
Other versions
EP1917967A4 (en
Inventor
Michio Tani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1917967A1 publication Critical patent/EP1917967A1/en
Publication of EP1917967A4 publication Critical patent/EP1917967A4/en
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to an anti-AIDS agent, and more particularly to an anti-AIDS agent that contains, as the active ingredients, Melastoma villosum Lodd., Dipterocarpus obtusifolius Teijsm ex Miq., Lyophyllum aggregatum, Dictyophora indusiata, pu-erh tea, mentha and stevia.
  • AIDS refers to a serious immunodeficiency syndrome caused by infection of a human immunodeficiency virus (HIV) which is an etiologic virus of AIDS.
  • HAV human immunodeficiency virus
  • crude drug and Chinese herbal medicine have been traditionally used for treatment and prevention of diseases from ancient times. Such crude drug and Chinese herbal medicine are typically proved to be of sufficient security, which can, therefore, be taken free of care. Some of them have a remarkable anti-virus effect of suppressing virus propagation.
  • some crude drugs have been reported which are for use of preventing AIDS virus infection, and of preventing and treating AIDS symptoms.
  • an extract of plant body of stevia prevents an HIV virus from adhering to, invading in, and associating with lymphocytes; and that, more particularly, said extract hinders binding of a CD4 molecule of lymphocytes to a gp 120 molecule of an HIV (see, for example, Laid-open Patent Publication No. H11-335292 ).
  • An anti-HIV activation material is known that is obtained in the following process: preparing an extract of mentha by using water, and refining the extract by way of DEAE negative ion exchange chromatography (see, for example, Laid-open Patent Publication No. H11-005745 ).
  • An AIDS medical drug such as one containing catechin or tannin (see, for example, Laid-open Patent Publication No. 2004-210762 ). It is also known that a Dictyophora indusiata-derived ingredient is absorbed in a human body through the mucous membrane to stimulate and activate the mucosal immunity, and that some beneficial effects can thus be expected such as an anti-tumor effect and an effect beneficial for treatment and remedy of infectious diseases caused by virus like AIDS, bacteria or the like (see, for example, WO2002/087603 pamphlet).
  • a drug product helps activate the immunization of a patient suffering from a disease like AIDS when the patient has an extremely low activity of the helper T cell
  • said drug product is prepared in the method comprising the steps of: dissolving a hydrothermal extract of Hypsizigus marmoreus in a lower alcohol solution; removing insoluble matters therefrom; mixing the solution with at least one selected from the group consisting of Okara paste, chlorella, spirulina, yeast extract, powdered royal extract and powdered propolis; and formulating the mixture into a drug product (see, for example, Laid-open Patent Publication No. 2004-059558 ).
  • a drug having much more beneficial effect and much less side effect than any one of the above-mentioned therapeutic agents.
  • Melastoma villosum Lodd. Dipterocarpus obtusifolius Teijsm ex Miq. and pu-erh tea have an anti-AIDS effect.
  • the present invention is intended to provide an anti-AIDS agent which is made of crude drugs available from natural products, and which is thus quite safe and secure for long-term regular use, free from any such serious side effects as can be observed in chemical drugs.
  • an anti-AIDS agent containing, as the active ingredients, one or more components selected from the group consisting of Lyophyllum aggregatum, Dictyophora indusiata, pu-erh tea, mentha and stevia.
  • the anti-AIDS agent of the present invention exhibits a remarkable anti-AIDS activity through continuous use thereof. Being made of crude drugs and food materials that have traditionally been used safe and secure, the inventive anti-AIDS agent is quite safe and secure, free from any such serious side effects as can be observed in chemical drugs, and the inventive drug can be prepared at a lower cost owing to the easy availability of the raw materials to be used for the preparation. Also, the number of AIDS virus will be reduced by taking the inventive anti-AIDS drug through daily life.
  • a leaf portion of Melastoma villosum Lodd. and a fruit portion of Dipterocarpus obtusifolius Teijsm ex Miq. are preferably used for the inventive anti-AIDS agent.
  • their dried substances have been traditionally used as crude drug throughout the Southeast Asia region including Thailand; hence these two substances do not pose any safety problem.
  • Lyophyllum aggregatum (academic name: Lyophyllum shimeji), which is an ingredient for the inventive agent, is a type of mushroom classified into Lyohyllum, Tricholomataceae. This mushroom grows densely in a copse of quercus serrata, sawtooth oak and the like, and has traditionally been eaten; hence this mushroom does not pose any safety problem.
  • Dictyophora indusiata (academic name: Dictyophora indusiata), which is an ingredient for the inventive agent, is a type of mushroom classified into Phallus. This mushroom grows gregariously or individually on the ground of a bamboo grove, broadleaf forest and the like, and has traditionally been used for Chinese dishes etc.; hence this mushroom does not pose any safety problem.
  • Pu-erh tea which is an ingredient for the inventive agent, is a type of fermented green tea, the production method thereof comprising fermentation of green tea with aspergillus for more than three years. Pu-erh tea is also called black tea in China where said tea has been drunk for more than 1700 years, and hence does not pose any safety problem.
  • Mentha (academic name: Mentha arvensis L.), which is an ingredient for the inventive agent, is a perennial plant classified into Mentha arvensis var. piperascens, Lamiaceae. Mentha, rich in menthol, has traditionally been applied for fragrance or medicinal use, and hence does not pose any safety problem.
  • Stevia which is an ingredient for the inventive agent, is Stevia rebaudiana Bertoni, a perennial plant originated from South America, and classified into Asteraceae. Stevia has been generally used as a sweetener etc., and hence does not pose any safety problem.
  • the anti-AIDS agent of the present invention can also be prepared as a hydrothermal extract of Melastoma villosum Lodd., Dipterocarpus obtusifolius Teijsm ex Miq., Lyophyllum aggregatum, Dictyophora indusiata, pu-erh tea, mentha and stevia.
  • these ingredients can be served raw for hydrothermal extraction, but more preferably, they are dried before hydrothermal extraction. Still more preferably, the dried substances are further roasted before hydrothermal extraction. It is also beneficial to spray-dry or freeze-dry the hydrothermal extract solution to be taken as extract powder, granulated powder, tablets or the like. It is still workable that the inventive anti-AIDS agent is taken in the form of dried or roasted fragments, without going through the process of hydrothermal extraction.
  • Said dried or roasted fragments can be hydrothermally extracted without any pretreatment; but from the practical point of view, further pulverization of the fragments is preferably conducted before extraction.
  • a non-limiting example of weight ratio between hot water used as extraction solvent and said dried or roasted fragments is 10-50: 1; more particularly, 20-40: 1 in terms of operational efficiency of the extraction.
  • Efficient extraction is expected at high temperature, though somewhat low temperature is also acceptable for sufficient extraction; and in particular, the temperature is preferably within the range of 70 to 100°C. Extraction time is properly determined according to the temperature, such that the active ingredients are successfully extracted.
  • the extraction is implemented under pressurized, non-pressurized or depressurized conditions. More particularly, the preferable extraction condition is at normal pressures, within the temperature range of 85 to 100°C, the extraction time being between 30 and 60 minutes.
  • Melastoma villosum Lodd. Dipterocarpus obtusifolius Teijsm ex Miq.
  • Lyophyllum aggregatum Dictyophora indusiata, pu-erh tea, mentha and stevia, each being dried
  • they are coarsely pulverized before being roasted.
  • coarse pulverization of said dried substances conventional methods are applied using a crusher etc. to create particles of between 0.2 and 2.0 mm in size. Examples of said conventional method include sand roasting, wire mesh roasting, hot-air roasting and microwave oven roasting.
  • Roasting conditions such as roasting time and temperature are properly determined according to the amount of the mixture to be roasted at one time. For example, in case of roasting 100g of the mixture, the preferable temperature is 110-130°C and the preferable time is 10-18 minutes.
  • the dry weight ratio of all of said ingredients to be blended in the inventive anti-AIDS agent namely, Melastoma villosum Lodd., Dipterocarpus obtusifolius Teijsm ex Miq., Lyophyllum aggregatum, Dictyophora indusiata, pu-erh tea, mentha and stevia, is preferably 2-5: 2-5: 1-4: 1-4: 0.5-2: 0.5-2; and more preferably, 3: 3: 2: 2: 2: 1: 1.
  • Non-limiting examples of administration methods of the inventive anti-AIDS agent comprise rectal administration, nasal administration, buccal administration, sublingual administration, vaginal administration, intramuscular administration, subcutaneous administration and intravenous administration.
  • An oral administration is the most preferable for the inventive agent.
  • the formulation of the inventive anti-AIDS agent can be properly selected depending on the administration route and so on.
  • formulation suitable for oral administration include tablets, capsules, powdered formulation, subtle granules, granular formulation, liquid formulation and syrup formulation.
  • formulation suitable for parenteral administration include injectable solution, intravenous fluids, suppository, inhaler, transdermal formulation, transmucosal formulation and adhesive formulation.
  • Said injectable solution may contain any one of the formulations for intravenous injection, intramuscular injection, subcutaneous injection and intravenous instillation; in particular, the most preferable one is the oral formulation.
  • the anti-AIDS agent of the present invention may, according to the necessity, further contain such additives as are permissible in terms of pharmacology and galenical pharmacy.
  • additives may include fillers, disintegrants/disintegration aids, binder, lubricant, coating agent, pigment, diluents, base material, dissolving agent/dissolving aids, tonicity agent, pH regulator, stabilizing agent, propellant, adhesive and moistening agent.
  • Combination of these additives according to the usage will provide the inventive anti-AIDS agent with a variety of additional effects.
  • a configuration of the anti-AIDS agent can, where appropriate, be designed such that anti-AIDS active substances will be sustainedly released.
  • Another configuration can be designed such that the anti-AIDS active substances will be intensively released at a targeted portion of a human body at which application of the substances is required.
  • sustained release preparation and drug delivery system can be designed and produced according to the method well-known to those skilled in the art in the drug formulation industry.
  • the inventive anti-AIDS agent may contain organic or inorganic carriers.
  • examples of said carriers include lactose, amylum, vegetable and animal fat and fatty oil.
  • a dose of the inventive anti-AIDS agent can be properly determined in consideration of a variety of conditions such as the purpose of treatment or preventative care; the patient's sex, weight and age; the type and extent of the disease; drug formulation; administration route and number of doses.
  • the suitable dosage amount a day is 9-30g of the dried mixture, which is to be taken either after hydrothermal extraction, or after roasting and then hydrothermal extraction.
  • the hydrothermal extract solution is spray-dried or freeze-dried to be taken as extract powder, granules, tablets or the like
  • the suitable dosage amount is 4.0-7.0g of the dried mixture.
  • the inventive anti-AIDS agent can be blended in common foods including soups, beverages (juice, sake, mineral water, coffee, tea etc.), confectionaries (gum, candy, chocolate, snack, jelly etc.), noodles (soba, udon, ramen etc.); health food products and dietary supplements (nutritious drink etc.). This will allow for comfortable daily consumption of the inventive anti-AIDS agent.
  • the concentration level of the inventive anti-AIDS agent in food or beverage can be changed depending on the type of the food or beverage; the preferable daily consumption amount of the extract powder, prepared through spray-drying and freeze-drying the hydrothermal extract solution, is 2.0-12.0g, and more preferably, 4.0-7.0g. Said concentration level is a non-limiting example that can be properly changed depending on a variety of circumstances.
  • the inventive anti-AIDS agent was provided for 24 AIDS cases to be taken twice a day, said agent having been extracted in hot water of 90-100°C for 40 minutes. Periodical blood drawings were carried out during the intake period to measure the concentration level of HIV antigen RNA. The result is shown in FIG. 1 .
  • FIG. 1 It is apparent from FIG. 1 that the concentration level of HIV antigen RNA significantly decreased after dosing the present invention. The result shows that the present invention clearly has the effect of reducing the number of AIDS virus. Therefore, it is proved that the present invention is quite effective as an anti-AIDS agent.
  • FIG. 1 is a graph showing the average concentration level of HIV antigen RNA in the blood of 24 AIDS patients continuously taking the anti-AIDS agent of the present invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

An anti-AIDS agent which comprises, as the active ingredients, one or more components selected from the group consisting of Melastoma villosum Lodd., Dipterocarpus obtusifolius Teijsm ex Miq., Lyophyllum aggregatum, Dictyophora indusiata, pu-erh tea, mentha and stevia. Since the foods having been confirmed as safe in practice are employed, this agent is completely safe to take over a long time.

Description

    Technical Field
  • The present invention relates to an anti-AIDS agent, and more particularly to an anti-AIDS agent that contains, as the active ingredients, Melastoma villosum Lodd., Dipterocarpus obtusifolius Teijsm ex Miq., Lyophyllum aggregatum, Dictyophora indusiata, pu-erh tea, mentha and stevia.
    • Background Art
  • AIDS refers to a serious immunodeficiency syndrome caused by infection of a human immunodeficiency virus (HIV) which is an etiologic virus of AIDS. In Japan and China, crude drug and Chinese herbal medicine have been traditionally used for treatment and prevention of diseases from ancient times. Such crude drug and Chinese herbal medicine are typically proved to be of sufficient security, which can, therefore, be taken free of care. Some of them have a remarkable anti-virus effect of suppressing virus propagation. In particular, some crude drugs have been reported which are for use of preventing AIDS virus infection, and of preventing and treating AIDS symptoms.
  • For example, it is known that an extract of plant body of stevia, mainly a stem and a leaf thereof, prevents an HIV virus from adhering to, invading in, and associating with lymphocytes; and that, more particularly, said extract hinders binding of a CD4 molecule of lymphocytes to a gp 120 molecule of an HIV (see, for example, Laid-open Patent Publication No. H11-335292 ). An anti-HIV activation material is known that is obtained in the following process: preparing an extract of mentha by using water, and refining the extract by way of DEAE negative ion exchange chromatography (see, for example, Laid-open Patent Publication No. H11-005745 ). An AIDS medical drug is known such as one containing catechin or tannin (see, for example, Laid-open Patent Publication No. 2004-210762 ). It is also known that a Dictyophora indusiata-derived ingredient is absorbed in a human body through the mucous membrane to stimulate and activate the mucosal immunity, and that some beneficial effects can thus be expected such as an anti-tumor effect and an effect beneficial for treatment and remedy of infectious diseases caused by virus like AIDS, bacteria or the like (see, for example, WO2002/087603 pamphlet). It is further known that a drug product helps activate the immunization of a patient suffering from a disease like AIDS when the patient has an extremely low activity of the helper T cell, where said drug product is prepared in the method comprising the steps of: dissolving a hydrothermal extract of Hypsizigus marmoreus in a lower alcohol solution; removing insoluble matters therefrom; mixing the solution with at least one selected from the group consisting of Okara paste, chlorella, spirulina, yeast extract, powdered royal extract and powdered propolis; and formulating the mixture into a drug product (see, for example, Laid-open Patent Publication No. 2004-059558 ). However, what has been desired to be developed is a drug having much more beneficial effect and much less side effect than any one of the above-mentioned therapeutic agents.
  • And it has not been known that Melastoma villosum Lodd., Dipterocarpus obtusifolius Teijsm ex Miq. and pu-erh tea have an anti-AIDS effect.
    • Disclosure of the Invention Problem to be Solved by the Invention
  • Bearing these circumstances in mind, the present invention is intended to provide an anti-AIDS agent which is made of crude drugs available from natural products, and which is thus quite safe and secure for long-term regular use, free from any such serious side effects as can be observed in chemical drugs.
    Means for Solving the Problem
  • This object is achieved by using an anti-AIDS agent containing, as the active ingredients, one or more components selected from the group consisting of Lyophyllum aggregatum, Dictyophora indusiata, pu-erh tea, mentha and stevia.
    • Effect of the Invention
  • The anti-AIDS agent of the present invention exhibits a remarkable anti-AIDS activity through continuous use thereof. Being made of crude drugs and food materials that have traditionally been used safe and secure, the inventive anti-AIDS agent is quite safe and secure, free from any such serious side effects as can be observed in chemical drugs, and the inventive drug can be prepared at a lower cost owing to the easy availability of the raw materials to be used for the preparation. Also, the number of AIDS virus will be reduced by taking the inventive anti-AIDS drug through daily life.
  • The embodiment of the present invention will be described in detail hereinafter.
    • Best Mode for Carrying out the Invention
  • A leaf portion of Melastoma villosum Lodd. and a fruit portion of Dipterocarpus obtusifolius Teijsm ex Miq. are preferably used for the inventive anti-AIDS agent. In particular, their dried substances have been traditionally used as crude drug throughout the Southeast Asia region including Thailand; hence these two substances do not pose any safety problem. Lyophyllum aggregatum (academic name: Lyophyllum shimeji), which is an ingredient for the inventive agent, is a type of mushroom classified into Lyohyllum, Tricholomataceae. This mushroom grows densely in a copse of quercus serrata, sawtooth oak and the like, and has traditionally been eaten; hence this mushroom does not pose any safety problem. Dictyophora indusiata (academic name: Dictyophora indusiata), which is an ingredient for the inventive agent, is a type of mushroom classified into Phallus. This mushroom grows gregariously or individually on the ground of a bamboo grove, broadleaf forest and the like, and has traditionally been used for Chinese dishes etc.; hence this mushroom does not pose any safety problem. Pu-erh tea, which is an ingredient for the inventive agent, is a type of fermented green tea, the production method thereof comprising fermentation of green tea with aspergillus for more than three years. Pu-erh tea is also called black tea in China where said tea has been drunk for more than 1700 years, and hence does not pose any safety problem. Mentha (academic name: Mentha arvensis L.), which is an ingredient for the inventive agent, is a perennial plant classified into Mentha arvensis var. piperascens, Lamiaceae. Mentha, rich in menthol, has traditionally been applied for fragrance or medicinal use, and hence does not pose any safety problem. Stevia, which is an ingredient for the inventive agent, is Stevia rebaudiana Bertoni, a perennial plant originated from South America, and classified into Asteraceae. Stevia has been generally used as a sweetener etc., and hence does not pose any safety problem.
  • The anti-AIDS agent of the present invention can also be prepared as a hydrothermal extract of Melastoma villosum Lodd., Dipterocarpus obtusifolius Teijsm ex Miq., Lyophyllum aggregatum, Dictyophora indusiata, pu-erh tea, mentha and stevia. In this case, these ingredients can be served raw for hydrothermal extraction, but more preferably, they are dried before hydrothermal extraction. Still more preferably, the dried substances are further roasted before hydrothermal extraction. It is also beneficial to spray-dry or freeze-dry the hydrothermal extract solution to be taken as extract powder, granulated powder, tablets or the like. It is still workable that the inventive anti-AIDS agent is taken in the form of dried or roasted fragments, without going through the process of hydrothermal extraction.
  • Said dried or roasted fragments can be hydrothermally extracted without any pretreatment; but from the practical point of view, further pulverization of the fragments is preferably conducted before extraction. A non-limiting example of weight ratio between hot water used as extraction solvent and said dried or roasted fragments is 10-50: 1; more particularly, 20-40: 1 in terms of operational efficiency of the extraction. Efficient extraction is expected at high temperature, though somewhat low temperature is also acceptable for sufficient extraction; and in particular, the temperature is preferably within the range of 70 to 100°C. Extraction time is properly determined according to the temperature, such that the active ingredients are successfully extracted. The extraction is implemented under pressurized, non-pressurized or depressurized conditions. More particularly, the preferable extraction condition is at normal pressures, within the temperature range of 85 to 100°C, the extraction time being between 30 and 60 minutes.
  • In regard to the roasting method, Melastoma villosum Lodd., Dipterocarpus obtusifolius Teijsm ex Miq., Lyophyllum aggregatum, Dictyophora indusiata, pu-erh tea, mentha and stevia, each being dried, can be roasted without any pretreatment; but it is preferred, from the practical point of view, that they are coarsely pulverized before being roasted. For coarse pulverization of said dried substances, conventional methods are applied using a crusher etc. to create particles of between 0.2 and 2.0 mm in size. Examples of said conventional method include sand roasting, wire mesh roasting, hot-air roasting and microwave oven roasting. Roasting conditions such as roasting time and temperature are properly determined according to the amount of the mixture to be roasted at one time. For example, in case of roasting 100g of the mixture, the preferable temperature is 110-130°C and the preferable time is 10-18 minutes.
  • The dry weight ratio of all of said ingredients to be blended in the inventive anti-AIDS agent, namely, Melastoma villosum Lodd., Dipterocarpus obtusifolius Teijsm ex Miq., Lyophyllum aggregatum, Dictyophora indusiata, pu-erh tea, mentha and stevia, is preferably 2-5: 2-5: 1-4: 1-4: 1-4: 0.5-2: 0.5-2; and more preferably, 3: 3: 2: 2: 2: 1: 1.
  • Non-limiting examples of administration methods of the inventive anti-AIDS agent, including oral and parenteral administrations, comprise rectal administration, nasal administration, buccal administration, sublingual administration, vaginal administration, intramuscular administration, subcutaneous administration and intravenous administration. An oral administration is the most preferable for the inventive agent. Besides, the formulation of the inventive anti-AIDS agent can be properly selected depending on the administration route and so on. Examples of formulation suitable for oral administration include tablets, capsules, powdered formulation, subtle granules, granular formulation, liquid formulation and syrup formulation. Examples of formulation suitable for parenteral administration include injectable solution, intravenous fluids, suppository, inhaler, transdermal formulation, transmucosal formulation and adhesive formulation. Said injectable solution may contain any one of the formulations for intravenous injection, intramuscular injection, subcutaneous injection and intravenous instillation; in particular, the most preferable one is the oral formulation.
  • The anti-AIDS agent of the present invention may, according to the necessity, further contain such additives as are permissible in terms of pharmacology and galenical pharmacy. Examples of said additives may include fillers, disintegrants/disintegration aids, binder, lubricant, coating agent, pigment, diluents, base material, dissolving agent/dissolving aids, tonicity agent, pH regulator, stabilizing agent, propellant, adhesive and moistening agent. Combination of these additives according to the usage will provide the inventive anti-AIDS agent with a variety of additional effects. For example, a configuration of the anti-AIDS agent can, where appropriate, be designed such that anti-AIDS active substances will be sustainedly released. Another configuration can be designed such that the anti-AIDS active substances will be intensively released at a targeted portion of a human body at which application of the substances is required. Such sustained release preparation and drug delivery system can be designed and produced according to the method well-known to those skilled in the art in the drug formulation industry.
  • The inventive anti-AIDS agent may contain organic or inorganic carriers. Examples of said carriers include lactose, amylum, vegetable and animal fat and fatty oil.
  • A dose of the inventive anti-AIDS agent can be properly determined in consideration of a variety of conditions such as the purpose of treatment or preventative care; the patient's sex, weight and age; the type and extent of the disease; drug formulation; administration route and number of doses. In the case of oral administration, the suitable dosage amount a day is 9-30g of the dried mixture, which is to be taken either after hydrothermal extraction, or after roasting and then hydrothermal extraction. Where the hydrothermal extract solution is spray-dried or freeze-dried to be taken as extract powder, granules, tablets or the like, the suitable dosage amount is 4.0-7.0g of the dried mixture.
  • Next, the inventive anti-AIDS agent can be blended in common foods including soups, beverages (juice, sake, mineral water, coffee, tea etc.), confectionaries (gum, candy, chocolate, snack, jelly etc.), noodles (soba, udon, ramen etc.); health food products and dietary supplements (nutritious drink etc.). This will allow for comfortable daily consumption of the inventive anti-AIDS agent.
  • Also, the concentration level of the inventive anti-AIDS agent in food or beverage can be changed depending on the type of the food or beverage; the preferable daily consumption amount of the extract powder, prepared through spray-drying and freeze-drying the hydrothermal extract solution, is 2.0-12.0g, and more preferably, 4.0-7.0g. Said concentration level is a non-limiting example that can be properly changed depending on a variety of circumstances.
    • Examples
  • The present invention is further described with reference to the following examples, which should not be construed to limit the scope of the invention.
    • Example 1: Preparation of Anti-AIDS Agent
  • 3.0g of dried Melastoma villosum Lodd., 3.0g of dried Dipterocarpus obtusifolius Teijsm ex Miq., 2.0g of dried Lyophyllum aggregatum, 2.0g of dried Dictyophora indusiata, 2.0g of dried pu-erh tea, 1.0g of dried mentha and 1.0g of dried stevia were mixed, coarsely pulverized, and roasted at 115° C for 16 minutes to prepare the anti-AIDS agent of the present invention.
    • Example 2: Preparation of Anti-AIDS Agent
  • 3.0g of dried Melastoma villosum Lodd., 3.0g of dried Dipterocarpus obtusifolius Teijsm ex Miq., 2.0g of dried Lyophyllum aggregatum, 2.0g of dried Dictyophora indusiata, 2.0g of dried pu-erh tea, 1.0g of dried mentha and 1.0g of dried stevia were mixed and coarsely pulverized to prepare the anti-AIDS agent of the present invention.
    • Experimental example 1
  • Clinical trial for measuring the anti-AIDS effect of the present invention was conducted as described below.
  • The inventive anti-AIDS agent was provided for 24 AIDS cases to be taken twice a day, said agent having been extracted in hot water of 90-100°C for 40 minutes. Periodical blood drawings were carried out during the intake period to measure the concentration level of HIV antigen RNA. The result is shown in FIG. 1.
  • It is apparent from FIG. 1 that the concentration level of HIV antigen RNA significantly decreased after dosing the present invention. The result shows that the present invention clearly has the effect of reducing the number of AIDS virus. Therefore, it is proved that the present invention is quite effective as an anti-AIDS agent.
    • Brief Description of the Drawings
  • FIG. 1 is a graph showing the average concentration level of HIV antigen RNA in the blood of 24 AIDS patients continuously taking the anti-AIDS agent of the present invention.

Claims (5)

  1. An anti-AIDS agent which contains, as the active ingredients, one or more components selected from the group consisting of Melastoma villosum Lodd., Dipterocarpus obtusifolius Teijsm ex Miq., Lyophyllum aggregatum, Dictyophora indusiata, pu-erh tea, mentha and stevia.
  2. The anti-AIDS agent according to Claim 1, wherein at least one ingredient of the group consisting of Melastoma villosum Lodd., Dipterocarpus obtusifolius Teijsm ex Miq., Lyophyllum aggregatum, Dictyophora indusiata, pu-erh tea, mentha and stevia is dried.
  3. The anti-AIDS agent according to Claim 1 or 2, wherein the at least one ingredient of the group consisting of Melastoma villosum Lodd., Dipterocarpus obtusifolius Teijsm ex Miq., Lyophyllum aggregatum, Dictyophora indusiata, pu-erh tea, mentha and stevia is further roasted.
  4. The anti-AIDS agent according to any one of Claims 1 to 3, wherein the dry weight ratio of Melastoma villosum Lodd., Dipterocarpus obtusifolius Teijsm ex Miq., Lyophyllum aggregatum, Dictyophora indusiata, pu-erh tea, mentha and stevia is 2-5: 2-5: 1-4: 1-4: 1-4: 0.5-2: 0.5-2.
  5. The anti-AIDS agent according to any one of Claims 1 to 4, wherein the dry weight ratio of Melastoma villosum Lodd., Dipterocarpus obtusifolius Teijsm ex Miq., Lyophyllum aggregatum, Dictyophora indusiata, pu-erh tea, mentha and stevia is 3: 3: 2: 2: 2: 1: 1.
EP05751388A 2005-06-20 2005-06-20 Anti-aids drug Withdrawn EP1917967A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2005/011297 WO2006137122A1 (en) 2005-06-20 2005-06-20 Anti-aids drug

Publications (2)

Publication Number Publication Date
EP1917967A1 true EP1917967A1 (en) 2008-05-07
EP1917967A4 EP1917967A4 (en) 2011-08-17

Family

ID=37570175

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05751388A Withdrawn EP1917967A4 (en) 2005-06-20 2005-06-20 Anti-aids drug

Country Status (5)

Country Link
US (1) US7638146B2 (en)
EP (1) EP1917967A4 (en)
JP (1) JPWO2006137122A1 (en)
CA (1) CA2612945A1 (en)
WO (1) WO2006137122A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101440489B1 (en) * 2011-06-29 2014-09-17 한국생명공학연구원 A pharmaceutical composition comprising extract of Dipterocarpus obtusifolius Teijsm. Ex Miq. for prevention and treatment of inflammatory diseases or allergic disease
CN106472510A (en) * 2016-10-10 2017-03-08 贵州省生物研究所 The application of dictyophora phalloidea cap activity powder, preparation method and activity powder

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010018546A (en) * 2008-07-10 2010-01-28 Nippon Zettoc Co Ltd Collagenase inhibitor, external preparation for skin, oral composition and food
CN101618050B (en) * 2009-07-23 2011-06-15 无限极（中国）有限公司 Compound fungus polysaccharide with function of enhancing immunity and application thereof
KR101325215B1 (en) 2010-08-24 2013-11-04 한국 한의학 연구원 Pharmaceutical composition for the prevention and treatment of diabetic complications containing the extracts or fractions of Melastoma sanguineum as active ingredient
WO2012026748A2 (en) * 2010-08-24 2012-03-01 한국한의학연구원 Pharmaceutical composition containing melastoma sanguineum extracts or fractions thereof as active ingredients for preventing and treating diabetic complications
KR101951782B1 (en) * 2010-10-25 2019-02-25 (주)아모레퍼시픽 Cosmetic composition for whitening containing green tea extract
WO2019189292A1 (en) * 2018-03-27 2019-10-03 株式会社雪国まいたけ Agent for treating and/or preventing viral infection
KR102079761B1 (en) * 2018-05-14 2020-02-20 서울대학교산학협력단 A recombinant BCG expressing HIV-1 p24 using a pMyong2 vector system and use as a HIV-1 vaccine thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3801900A1 (en) * 1988-01-23 1989-09-07 Nink Karl Heinz Use of terpene-containing essential oils for controlling Aids and Arc, and pharmaceutical compositions containing them

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5558080A (en) * 1978-10-20 1980-04-30 Tsuneo Suzuki Preparation of sugarless sweetener for infusion
JP3072321B2 (en) 1997-06-13 2000-07-31 工業技術院長 Anti-HIV active substance and method for producing the same
JPH11335292A (en) * 1998-03-26 1999-12-07 Naohiko Sato Anti-hiv active substance derived from stevia
TWI300714B (en) 2001-04-27 2008-09-11 Ajinomoto Kk Immunopotentiators
JP2004059558A (en) * 2002-07-29 2004-02-26 Seimei Kagaku Kenkyusho:Kk Method for collecting physiologically active substance from fungus, preparation of physiologically active substance of the same and use of the same
JP2004210762A (en) * 2003-01-08 2004-07-29 Masami Uchiyama Catechin tablet, or the like, against aids

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3801900A1 (en) * 1988-01-23 1989-09-07 Nink Karl Heinz Use of terpene-containing essential oils for controlling Aids and Arc, and pharmaceutical compositions containing them

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AMZAZI S ET AL: "HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INHIBITORY ACTIVE OF MENTHA LONGIFOLIA", THERAPIE, SOCIETE FRANCAISE DE PHARMACOLOGIE ET DE THERAPEUTIQUE, FR, vol. 58, no. 6, 1 November 2003 (2003-11-01), pages 531-534, XP008065646, ISSN: 0040-5957, DOI: DOI:10.2515/THERAPIE:2003086 *
LAM S K ET AL: "First simultaneous isolation of a ribosome inactivating protein and an antifungal protein from a mushroom (Lyophyllum shimeji) together with evidence for synergism of their antifungal effects", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 393, no. 2, 15 September 2001 (2001-09-15), pages 271-280, XP002648903, ISSN: 0003-9861 *
SCHÜPBACH JÖRG: "Viral RNA and p24 antigen as markers of HIV disease and antiretroviral treatment success.", INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, vol. 132, no. 3, November 2003 (2003-11), pages 196-209, XP002648905, ISSN: 1018-2438 *
See also references of WO2006137122A1 *
TAKAHASHI K ET AL: "In vitro anti-HIV activity of extract from Stevia rebaudiana", ANTIVIRAL RESEARCH, vol. 37, no. 3, March 1998 (1998-03), page A59, XP002648904, & ELEVENTH INTERNATIONAL CONFERENCE ON ANTIVIRAL RESEARCH; SAN DIEGO, CALIFORNIA, USA; APRIL 5-10, 1998 ISSN: 0166-3542 *
XU HONG-XI ET AL: "INHIBITORY ACTIVITY OF FLAVONOIDS AND TANNINS AGAINST HIV-1 PROTEASE", BIOLOGICAL & PHARMACEUTICAL BULLETIN (OF JAPAN), PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO, JP, vol. 23, no. 9, 1 September 2000 (2000-09-01), pages 1072-1076, XP001247378, ISSN: 0918-6158 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101440489B1 (en) * 2011-06-29 2014-09-17 한국생명공학연구원 A pharmaceutical composition comprising extract of Dipterocarpus obtusifolius Teijsm. Ex Miq. for prevention and treatment of inflammatory diseases or allergic disease
CN106472510A (en) * 2016-10-10 2017-03-08 贵州省生物研究所 The application of dictyophora phalloidea cap activity powder, preparation method and activity powder

Also Published As

Publication number Publication date
US7638146B2 (en) 2009-12-29
JPWO2006137122A1 (en) 2009-01-08
WO2006137122A1 (en) 2006-12-28
CA2612945A1 (en) 2006-12-28
EP1917967A4 (en) 2011-08-17
US20080199488A1 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
US7638146B2 (en) Anti-AIDS drug
CN1283296C (en) Gorge caring tea and its preparing process
CN114502184A (en) Pharmaceutical and food compositions for the prevention and treatment of coronavirus infection comprising Elaeagnus dulcis extract
CN106343567A (en) Noni oral liquid and preparing method thereof
KR101039110B1 (en) A water composition comprising Broussonetia kazinoki Sieb. for immunopotentiating
KR20160141027A (en) Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder
CN108096454A (en) A kind of pharmaceutical composition strengthened the body resistance to consolidate the constitution, improve immunity and preparation method thereof
CN101537143A (en) Chinese traditional medicine composition for curing chronic gastritis and preparation method thereof
CN102652561A (en) Vegetable protein food for treating micro-disease or assisting medicament in rehabilitating sick body and production method thereof
JP2004352626A (en) Anticholesterol agent containing plant-derived component
KR20130123947A (en) Immune enhancing and antiviral composition comprising extract of salvia miltiorrhiza bunge
CN107647074A (en) A kind of nourishing the stomach, stomach invigorating, the preparation method of dyspepsia hawthorn Chinese yam Hericium erinaceus pressed candy
KR102211523B1 (en) Pills for health foods and methods for manufacturing same
CN105477618A (en) Compound ampelopsis grossedentata blood-pressure-lowering tea and preparation method thereof
KR101413771B1 (en) A composition for anti-obesity comprising extract of big cone pine needle
CN101816708B (en) Chinese medicinal composition for curing rheumatism and preparation method thereof
KR20160082958A (en) Pharmaceutical composition for preventing or treating allergic diseases comprising extrat of Pterocarpus indicus Willd as an active ingredient
KR101154031B1 (en) Composition for Antifati gue containin g herbal mixture extract as in gredient compounds
JP6151419B2 (en) Polyphenol absorption accelerator
KR101588004B1 (en) Attractive pill using Great plantain and pockmark cabbage and making method of it
JP2006290794A (en) Plant fermentation product having anti-helicobacter pylori activity
KR102176394B1 (en) A composition for immune enhancement comprising taheebo extract
KR20130073048A (en) Functional food for recovering diabetes, hypertension and kidney disease
EA018343B1 (en) Compositon for enhancing immunity and use thereof
KR101904819B1 (en) Composition comprising Fermented Momordica charantia L. and Allium sativum L. using Amyloliquefaciens Bacillus Jis-1 for lowering blood glucose or preventing and treating diabetes mellitus

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071212

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1117767

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20110720

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 35/00 20060101AFI20110712BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20111019